Qiagen stock gains 7.7 percent as testing catalyst adds support

Published on 10/03/2026 at 23:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock posted Q2 revenue of USD 535.04 million, while EPS reached USD 0.62 against USD 0.60 consensus. Analysts set a mean target of USD 43.51.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen (ISIN NL0015002SN0) stock traded at USD 45.2920 on the NYSE on October 2, 2026, up 7.7 percent from the prior close. The move came as investors weighed a fresh diagnostic product milestone against a consensus target below the market price.

FDA clearance expands testing menu

On September 28, QIAGEN announced that US laboratories could access the complete QIAstat-Dx bloodstream infection portfolio after the FDA cleared a new panel, as StockTitan reported. The new test identifies 13 gram-negative bacterial targets and 18 antimicrobial resistance markers, while the two-panel portfolio covers 33 pathogen targets and 28 resistance markers.

The panel delivers results in about one hour, according to the company statement carried by StockTitan. The commercial value lies in extending an existing platform rather than introducing a standalone assay, giving laboratories a broader workflow for bloodstream infections.

Quarterly beat meets cautious targets

Qiagen reported Q2 2026 revenue of USD 535.04 million versus USD 527.50 million consensus, while EPS was USD 0.62 against USD 0.60 expected, according to MarketBeat on October 2, 2026. Revenue therefore exceeded consensus by USD 7.54 million, while EPS surpassed expectations by USD 0.02.

Valuation expectations are less uniform. MarketBeat cited a consensus Hold rating and an average 12-month target of USD 43.51, below the October 2 trading price. The same report said JPMorgan raised its target from USD 45.00 to USD 50.00 on August 7, 2026, while UBS cut its target from USD 52.00 to USD 47.00 on September 9, 2026, as Yahoo Finance reported.

Qiagen stock trades above consensus

Qiagen stock changed hands at USD 45.2920 on the NYSE on October 2, 2026, with 1,586,694 shares traded during the session and a market capitalization of USD 9.26 billion. The price was above the USD 43.51 consensus target, making the newly cleared diagnostic menu and execution against quarterly expectations the key figures for the next assessment.